-
Je něco špatně v tomto záznamu ?
Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study
A. Ruggeri, N. Santoro, JE. Galimard, K. Kalwak, M. Algeri, L. Zubarovskaya, K. Czyzewski, E. Skorobogatova, P. Sedlacek, C. Besley, A. Balduzzi, Y. Bertrand, J. Peristeri, F. Fagioli, M. Ifversen, J. Gozdzik, C. Peters, B. Versluijs, A. Biffi,...
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, srovnávací studie
NLK
Directory of Open Access Journals
od 1994
Free Medical Journals
od 1994
Freely Accessible Science Journals
od 1994
PubMed Central
od 2009
Europe PubMed Central
od 2009
Open Access Digital Library
od 1994-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1996
- MeSH
- akutní myeloidní leukemie * terapie mortalita MeSH
- cyklofosfamid * terapeutické užití aplikace a dávkování MeSH
- dítě MeSH
- haploidentická transplantace * metody MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- nemoc štěpu proti hostiteli * etiologie prevence a kontrola MeSH
- nepříbuzný dárce * MeSH
- předškolní dítě MeSH
- příprava pacienta k transplantaci * metody MeSH
- testování histokompatibility MeSH
- transplantace hematopoetických kmenových buněk * metody škodlivé účinky MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
In children with acute myeloid leukemia (AML) who lack a human leukocyte antigen (HLA) identical sibling, the donor can be replaced with an HLA-matched unrelated donor (MUD) or a haploidentical donor (haplo). We compared outcomes of patients <18 years with AML in first and second complete remission (CR1 and CR2) undergoing a hematopoietic stem cell transplantation (HCT) either with a MUD with anti-thymocyte globulin (ATG) (N=420) or a haplo HCT with post-transplant cyclophosphamide (PT-CY) (N=96) after a myeloablative conditioning regimen (MAC) between 2011 and 2021, reported to the European Society for Blood and Marrow Transplantation. A matched pair analysis was performed to adjust for differences among groups. The final analysis was performed on 253 MUD and 95 haplo-HCT. In the matched cohort, median age at HCT was 11.2 and 10 years and median year of HCT was 2017 and 2018, in MUD and haplo-HCT recipients, respectively. The risk of grade III-IV acute graft-versus-host disease (aGVHD) was significantly higher in the haplo group (hazard ratio [HR]=2.33, 95% confidence interval [CI]: 1.18-4.58; P=0.01). No significant differences were found in 2 years overall survival (OS; 78.4% vs. 71.5%; HR=1.39, 95% CI: 0.84-2.31; P=0.19), leukemia-free survival (LFS; 72.7% vs. 69.5%; HR=1.22, 95% CI: 0.76-1.95; P=0.41), CI of relapse (RI; 19.3% vs. 19.5%; HR=1.14, 95% CI: 0.62-2.08; P=0.68) non-relapse-mortality (NRM; 8% vs. 11%; HR=1.39, 95% CI: 0.66-2.93; P=0.39) and graft-versus-host free relapse-free survival (GRFS; 60.7% vs. 54.5%, HR=1.38, 95% CI: 0.95-2.02; P=0.09) after MUD and haplo-HCT respectively. Our study suggests that haplo-HCT with PT-CY is a suitable option to transplant children with AML lacking a matched related donor.
Belorussian Centre for Paediatric Oncology and Hematology Minsk
BMT Unit Sao Paolo University Sao Paolo Brasil
Bristol Royal Hospital for Children Dept of Paediatric Oncology BMT Bristol
Clinica di Oncoematologia Pediatrica Dipartimento di Pediatria Padova
Department of Health Sciences Magna Graecia University Catanzaro
Department of Medicine and Surgery Milano Bicocca University Monza
Department of Pediatric Hematology Oncology IRCCS Bambino Gesu Children' s Hospital Rome Italy
Hematology Unit Department of Oncology and Hematology Santo Spirito Hospital 65124 Pescara
Hematopoietic Stem Cell Transplantation Unit Fondazione IRCCS San Gerardo dei Tintori Monza Italy
HSCT Unit Department Hemato Oncology IRCSS Istituto G Gaslini
Institut d'Hematologie et d'Oncologie Pediatrique Lyon
IRCCS Azienda Ospedaliero Universitaria Bologna
IRCCS San Raffaele Scientific Institute Milano
Onco Ematologia Pediatrica Centro Trapianti Cellule Staminali Torino
Pediatric University Teaching Hospital BMT Unit 2 Children's Clinic Bratislava Slovakia
Prinses Maxima Centrum Utrecht
RM Gorbacheva Research Institute Pavlov University St Petersburg
St Anna Children's Hospital Department of Pediatrics Medical University of Vienna Vienna
St Sophia Children's hospital Oncology center Athens
The Russian Children' s Research Hospital Department of Bone Marrow Transplantation Moscow
University Hospital Motol Department of Paediatric Haematology and Oncology Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019951
- 003
- CZ-PrNML
- 005
- 20241024110830.0
- 007
- ta
- 008
- 241015s2024 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3324/haematol.2023.284445 $2 doi
- 035 __
- $a (PubMed)38186346
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Ruggeri, Annalisa $u IRCCS San Raffaele Scientific Institute, Milano. ruggeri.annalisa@hsr.it
- 245 10
- $a Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study / $c A. Ruggeri, N. Santoro, JE. Galimard, K. Kalwak, M. Algeri, L. Zubarovskaya, K. Czyzewski, E. Skorobogatova, P. Sedlacek, C. Besley, A. Balduzzi, Y. Bertrand, J. Peristeri, F. Fagioli, M. Ifversen, J. Gozdzik, C. Peters, B. Versluijs, A. Biffi, A. Prete, M. Faraci, I. Ghemlas, I. Bodova, O. Aleinikova, A. Dalissier, V. Rocha, S. Corbacioglu
- 520 9_
- $a In children with acute myeloid leukemia (AML) who lack a human leukocyte antigen (HLA) identical sibling, the donor can be replaced with an HLA-matched unrelated donor (MUD) or a haploidentical donor (haplo). We compared outcomes of patients <18 years with AML in first and second complete remission (CR1 and CR2) undergoing a hematopoietic stem cell transplantation (HCT) either with a MUD with anti-thymocyte globulin (ATG) (N=420) or a haplo HCT with post-transplant cyclophosphamide (PT-CY) (N=96) after a myeloablative conditioning regimen (MAC) between 2011 and 2021, reported to the European Society for Blood and Marrow Transplantation. A matched pair analysis was performed to adjust for differences among groups. The final analysis was performed on 253 MUD and 95 haplo-HCT. In the matched cohort, median age at HCT was 11.2 and 10 years and median year of HCT was 2017 and 2018, in MUD and haplo-HCT recipients, respectively. The risk of grade III-IV acute graft-versus-host disease (aGVHD) was significantly higher in the haplo group (hazard ratio [HR]=2.33, 95% confidence interval [CI]: 1.18-4.58; P=0.01). No significant differences were found in 2 years overall survival (OS; 78.4% vs. 71.5%; HR=1.39, 95% CI: 0.84-2.31; P=0.19), leukemia-free survival (LFS; 72.7% vs. 69.5%; HR=1.22, 95% CI: 0.76-1.95; P=0.41), CI of relapse (RI; 19.3% vs. 19.5%; HR=1.14, 95% CI: 0.62-2.08; P=0.68) non-relapse-mortality (NRM; 8% vs. 11%; HR=1.39, 95% CI: 0.66-2.93; P=0.39) and graft-versus-host free relapse-free survival (GRFS; 60.7% vs. 54.5%, HR=1.38, 95% CI: 0.95-2.02; P=0.09) after MUD and haplo-HCT respectively. Our study suggests that haplo-HCT with PT-CY is a suitable option to transplant children with AML lacking a matched related donor.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a akutní myeloidní leukemie $x terapie $x mortalita $7 D015470
- 650 _2
- $a dítě $7 D002648
- 650 12
- $a nepříbuzný dárce $7 D061349
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a cyklofosfamid $x terapeutické užití $x aplikace a dávkování $7 D003520
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $x škodlivé účinky $7 D018380
- 650 12
- $a haploidentická transplantace $x metody $7 D000075442
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a předškolní dítě $7 D002675
- 650 12
- $a nemoc štěpu proti hostiteli $x etiologie $x prevence a kontrola $7 D006086
- 650 12
- $a příprava pacienta k transplantaci $x metody $7 D019172
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a testování histokompatibility $7 D006650
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Santoro, Nicole $u Hematology Unit, Department of Oncology and Hematology, Santo Spirito Hospital, 65124 Pescara
- 700 1_
- $a Galimard, Jacques-Emmanuel $u EBMT Statistical Unit, Paris
- 700 1_
- $a Kalwak, Krzysztof $u Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw
- 700 1_
- $a Algeri, Mattia $u Department of Pediatric Hematology Oncology, IRCCS Bambino Gesu Children' s Hospital, Rome, Italy; Department of Health Sciences, Magna Graecia University, Catanzaro
- 700 1_
- $a Zubarovskaya, Ludmila $u RM Gorbacheva Research Institute, Pavlov University, St. Petersburg
- 700 1_
- $a Czyzewski, Krzysztof $u Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz
- 700 1_
- $a Skorobogatova, Elena $u The Russian Children' s Research Hospital, Department of Bone Marrow Transplantation, Moscow
- 700 1_
- $a Sedlacek, Petr $u University Hospital Motol Department of Paediatric Haematology and Oncology, Prague, Czech Republic
- 700 1_
- $a Besley, Caroline $u Bristol Royal Hospital for Children Dept. of Paediatric Oncology/BMT, Bristol
- 700 1_
- $a Balduzzi, Adriana $u Hematopoietic Stem Cell Transplantation Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; Department of Medicine and Surgery, Milano-Bicocca University, Monza
- 700 1_
- $a Bertrand, Yves $u Institut d'Hematologie et d'Oncologie Pediatrique, Lyon
- 700 1_
- $a Peristeri, Julia $u St Sophia Children's hospital Oncology center Athens
- 700 1_
- $a Fagioli, Franca $u Onco-Ematologia Pediatrica Centro Trapianti Cellule Staminali, Torino
- 700 1_
- $a Ifversen, Mariane $u Copenhagen University Hospital, Rigshospitalet, Dept of Children and Adolescents Medicine Copenhagen, Denmark
- 700 1_
- $a Gozdzik, Jolanta $u Department of Clinical Immunology and Transplantation Jagiellonian University Medical College, Children's Hospital in Krakow
- 700 1_
- $a Peters, Christina $u St. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, Vienna
- 700 1_
- $a Versluijs, Birgitta $u Prinses Maxima Centrum, Utrecht
- 700 1_
- $a Biffi, Alessandra $u Clinica di Oncoematologia Pediatrica, Dipartimento di Pediatria, Padova
- 700 1_
- $a Prete, Arcangelo $u IRCCS-Azienda Ospedaliero Universitaria, Bologna
- 700 1_
- $a Faraci, Maura $u HSCT Unit, Department Hemato-Oncology, IRCSS Istituto G. Gaslini; Genova
- 700 1_
- $a Ghemlas, Ibrahim $u Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
- 700 1_
- $a Bodova, Ivana $u Pediatric University Teaching Hospital BMT Unit, II Children's Clinic Bratislava, Slovakia
- 700 1_
- $a Aleinikova, Olga $u Belorussian Centre for Paediatric Oncology and Hematology Minsk
- 700 1_
- $a Dalissier, Arnaud $u EBMT Paris Study Unit, Paris
- 700 1_
- $a Rocha, Vanderson $u BMT Unit, Sao Paolo University, Sao Paolo, Brasil
- 700 1_
- $a Corbacioglu, Selim $u University of Regensburg, Regensburg
- 773 0_
- $w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 109, č. 7 (2024), s. 2122-2130
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38186346 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110824 $b ABA008
- 999 __
- $a ok $b bmc $g 2202277 $s 1231924
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 109 $c 7 $d 2122-2130 $e 20240701 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
- LZP __
- $a Pubmed-20241015
